Tremfya
Overview
Tremfya (brand name; active ingredient: guselkumab) is a human monoclonal antibody developed by Janssen, a biologic agent that selectively blocks the p19 subunit of interleukin-23 (IL-23) to suppress inflammatory responses. It is primarily used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It received U.S. FDA approval in 2017 and has since become a major treatment option for autoimmune diseases worldwide.
Main Content
Mechanism of Action
Tremfya binds to the p19 subunit of the IL-23 cytokine, interfering with its interaction with the IL-23 receptor. IL-23 is a cytokine essential for the differentiation and maintenance of Th17 cells, playing a key role in the pathophysiology of psoriasis and other inflammatory diseases. By blocking IL-23 signaling, Tremfya inhibits the production of inflammatory cytokines (e.g., IL-17, IL-22) and reduces inflammatory responses in the skin and joints.
Indications
- Plaque Psoriasis: Systemic treatment for adult moderate-to-severe plaque psoriasis (candidates for phototherapy or systemic therapy).
- Psoriatic Arthritis: Treatment of active psoriatic arthritis alone or in combination with methotrexate.
- Ankylosing Spondylitis: Treatment of active ankylosing spondylitis (additional FDA approval in 2023).
Clinical Efficacy
In clinical trials (VOYAGE 1, VOYAGE 2, DISCOVER-1, DISCOVER-2, etc.), Tremfya demonstrated superior skin lesion improvement (PASI 90, PASI 100 achievement rates) and joint symptom relief (ACR20, ACR50 response rates) compared to placebo. It also showed good tolerability and high durability of effect with long-term administration.
Administration
Tremfya is administered as a subcutaneous injection, given at weeks 0 and 4 initially, followed by maintenance doses every 8 weeks. It is provided as a pre-filled syringe or auto-injector for self-administration.
Side Effects and Precautions
The most common side effects include injection site reactions (redness, pain), upper respiratory tract infections, and headache. As an IL-23 inhibitor, there may be an increased risk of tuberculosis and opportunistic infections, so tuberculosis screening and infection testing are mandatory before administration. Additionally, cases of symptom exacerbation have been reported in patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis), requiring caution.
Drug Interactions
Tremfya inhibits cytokines (e.g., IL-23) that regulate CYP450 enzymes, potentially affecting the metabolism of CYP450 substrate drugs (e.g., warfarin, oral contraceptives). Monitoring of blood concentrations is recommended, especially when used with drugs having a narrow therapeutic range.
Recent Trends
As of 2024-2025, Tremfya is widely used as a first-line biologic agent for psoriasis and psoriatic arthritis, with its market share increasing following the expansion of its indication to ankylosing spondylitis. Recent studies have published data showing that Tremfya has a superior long-term safety profile compared to IL-17 inhibitors (e.g., secukinumab), particularly with a lower risk of tuberculosis reactivation. Additionally, a phase 3 clinical trial in pediatric psoriasis patients is ongoing, with potential FDA approval expected within 2025. As biosimilar competition intensifies, Janssen has launched a new auto-injector version with improved convenience for subcutaneous injection to enhance patient compliance.
Related Topics
- [[Biologic agents]]
- [[Psoriasis]]
- [[Autoimmune diseases]]